Biotech
Cliff Watch: The CFTR Modulator Grant Behind Vertex's Most Durable Cash Flows
Vertex's cystic-fibrosis franchise funds everything else it does. An older CFTR-modulator grant is a reminder that durability has a clock.
Latest Articles
12 articles indexedBiotech
The 2026 Biotech-Deal Map, Read Through the Patents That Underwrite It
Five themes drove therapeutics dealmaking this year. Each one traces to a specific, verifiable patent record — and the documents agree with the deal flow.
Cliff Watch
Biotech
Deal Sheet: A BCMA/TACI Antibody Grant — and the Kind of Licensing It Invites
Multiple-myeloma targets like BCMA are deal magnets. A June 2026 grant on a BCMA/TACI binder shows the asset shape behind the term sheets.
Biotech
Term Teardown: The Ionizable-Lipid Grant That Sits Under Every mRNA Deal's Economics
mRNA medicines live or die on delivery. A University of Pennsylvania lipid grant is the kind of upstream IP that quietly shapes royalty stacks across the field.
Biotech
R&D Ledger: The Precision-Oncology Grant Behind the Companion-Diagnostic Economics
Targeted cancer drugs need diagnostics to find their patients. A June 2026 grant on NTRK fusion detection shows the IP that decides a drug's addressable market.
Biotech
FDA Watch: The Gene-Edited Stem-Cell Documents Sitting Behind the Next Wave of Catalysts
Edited hematopoietic stem cells are a catalyst-rich category. Two recent records — an Editas application and a Stanford engraftment grant — show the document trail underneath.
Biotech
Burn Report: An Anti-VEGF Eye-Disease Grant and the Capital a Single Asset Demands
Retinal-disease programs are capital-hungry and IP-dense. A June 2026 grant on an eye-disorder treatment shows the asset a small-cap is financing.
Biotech
Deal Sheet: The CRISPR Therapeutics Grant That Puts a Floor Under the Pipeline's Value
Gene-editing valuations rest on the patent estate. A June 2026 CRISPR Therapeutics grant is one concrete brick — here is what it actually claims.
Biotech
Catalyst Calendar: The Tri-Agonist Application That Signals Where the Obesity Race Goes Next
A published application on GLP-1/GIP/amylin tri-agonists is a forward marker. Applications are not grants — but they tell you where the catalysts will cluster.
Biotech
Term Teardown: The Older GLP-1 Derivative Grants That Still Anchor the Semaglutide Cash Flows
The franchise everyone debates rests partly on patents granted in 2019. The earlier the grant, the closer the cliff — and the math is on the document.
Biotech
Reality Check: The Foundational CRISPR Grant That Shadows Every Gene-Editing Deal
Every gene-editing company tells a clean ownership story. The foundational-enzyme patents held by research institutes are the fact that complicates it.
Biotech
Deal Sheet: The Patent That Underwrites Lilly's GLP-1/GIP Franchise — and Every Deal Built on It
When a deal references the incretin franchise, the value sits in a method-of-use grant. Here is the actual document, and what it does and does not cover.